225Ac-rhPSMA-10.1

N/A

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug Name225Ac-rhPSMA-10.1
Drug Alias Name225actinium-labelled radiohybrid Prostate-Specific Membrane Antigen225actinium labelled PSMA (Blue Earth Therapeutics)
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlue Earth Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBlue Earth Therapeutics LtdUniversity College London
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A